Serina Therapeutics (NYSEAMERICAN:SER) Insider Sells 6,500 Shares

Serina Therapeutics, Inc. (NYSEAMERICAN:SER) insider Randall Moreadith sold 6,500 shares of the firm’s stock in a transaction dated Wednesday, January 28th. The stock was sold at an average price of $3.57, for a total value of $23,205.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Randall Moreadith also recently made the following trade(s):

• On Thursday, January 22nd, Randall Moreadith sold 2,500 shares of Serina Therapeutics stock. The stock was sold at an average price of $2.95, for a total transaction of $7,375.00.
• On Wednesday, January 21st, Randall Moreadith sold 2,000 shares of Serina Therapeutics stock. The stock was sold at an average price of $3.00, for a total value of $6,000.00.

Serina Therapeutics Stock Up 30.9%

Shares of SER stock traded up $0.84 during trading hours on Thursday, reaching $3.56. The company had a trading volume of 63,160,761 shares, compared to its average volume of 3,790,159. The firm has a market capitalization of $37.95 million, a PE ratio of -1.90 and a beta of 1.15. Serina Therapeutics, Inc. has a one year low of $1.71 and a one year high of $7.92.

About Serina Therapeutics

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.